{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:11:46Z","timestamp":1783771906235,"version":"3.55.0"},"publisher-location":"Cham","reference-count":146,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032121653","type":"print"},{"value":"9783032121660","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-3-032-12166-0_4","type":"book-chapter","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:15:06Z","timestamp":1783768506000},"page":"125-143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gut\u2013Liver Microbiome and Tumor Microenvironment in Metabolic Dysfunction-Associated Steatotic Liver Disease"],"prefix":"10.1007","author":[{"given":"Jeremy","family":"Chimene-Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Bromfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Gheewalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Mitten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Portincasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8334-0400","authenticated-orcid":false,"given":"Gyorgy","family":"Baffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"key":"4_CR1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nrgastro.2010.172","volume":"7","author":"A Abu-Shanab","year":"2010","unstructured":"Abu-Shanab A, Quigley EM (2010) The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 7:691\u2013701. https:\/\/doi.org\/10.1038\/nrgastro.2010.172","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4_CR2","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/hep.31417","volume":"73","author":"LJM Alferink","year":"2021","unstructured":"Alferink LJM et al (2021) Microbiomics, metabolomics, predicted metagenomics, and hepatic steatosis in a population-based study of 1355 adults. Hepatology 73:968\u2013982. https:\/\/doi.org\/10.1002\/hep.31417","journal-title":"Hepatology"},{"key":"4_CR3","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/hep.28709","volume":"65","author":"JP Arab","year":"2017","unstructured":"Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M (2017) Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology 65:350\u2013362. https:\/\/doi.org\/10.1002\/hep.28709","journal-title":"Hepatology"},{"key":"4_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12072-017-9798-x","volume":"12","author":"JP Arab","year":"2018","unstructured":"Arab JP, Martin-Mateos RM, Shah VH (2018) Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. Hepatol Int 12:24\u201333. https:\/\/doi.org\/10.1007\/s12072-017-9798-x","journal-title":"Hepatol Int"},{"key":"4_CR5","doi-asserted-by":"publisher","first-page":"G696","DOI":"10.1152\/ajpgi.00575.2004","volume":"289","author":"SY Archer","year":"2005","unstructured":"Archer SY et al (2005) The histone deacetylase inhibitor butyrate downregulates cyclin B1 gene expression via a p21\/WAF-1-dependent mechanism in human colon cancer cells. Am J Physiol Gastrointest Liver Physiol 289:G696\u2013703. https:\/\/doi.org\/10.1152\/ajpgi.00575.2004","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"4_CR6","doi-asserted-by":"publisher","first-page":"4286228","DOI":"10.1155\/2024\/4286228","volume":"2024","author":"S Aslam","year":"2024","unstructured":"Aslam S et al (2024) Potential target metabolites from gut microbiota against hepatocellular carcinoma: a network pharmacology and molecular docking study. Int J Microbiol 2024:4286228. https:\/\/doi.org\/10.1155\/2024\/4286228","journal-title":"Int J Microbiol"},{"key":"4_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/978-3-030-34025-4_5","volume":"1219","author":"G Baffy","year":"2020","unstructured":"Baffy G (2020) Gut microbiota and cancer of the host: colliding interests. Adv Exp Med Biol 1219:93\u2013107. https:\/\/doi.org\/10.1007\/978-3-030-34025-4_5","journal-title":"Adv Exp Med Biol"},{"key":"4_CR8","doi-asserted-by":"publisher","unstructured":"Banerjee R et al (2024) Circulating gut microbe-derived metabolites are associated with hepatocellular carcinoma. Biomedicines 12 https:\/\/doi.org\/10.3390\/biomedicines12091946","DOI":"10.3390\/biomedicines12091946"},{"key":"4_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20422-7","volume":"12","author":"J Behary","year":"2021","unstructured":"Behary J et al (2021) Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun 12: 187. https:\/\/doi.org\/10.1038\/s41467-020-20422-7","journal-title":"Nat Commun"},{"key":"4_CR10","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1017\/S0007114510001030","volume":"104","author":"RF Benus","year":"2010","unstructured":"Benus RF, van der Werf TS, Welling GW, Judd PA, Taylor MA, Harmsen HJ, Whelan K (2010) Association between Faecalibacterium prausnitzii and dietary fibre in colonic fermentation in healthy human subjects. Br J Nutr 104:693\u2013700. https:\/\/doi.org\/10.1017\/S0007114510001030","journal-title":"Br J Nutr"},{"key":"4_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.cld.2015.10.012","volume":"20","author":"J Boursier","year":"2016","unstructured":"Boursier J, Diehl AM (2016) Nonalcoholic fatty liver disease and the gut microbiome. Clin Liver Dis 20:263\u2013275. https:\/\/doi.org\/10.1016\/j.cld.2015.10.012","journal-title":"Clin Liver Dis"},{"key":"4_CR12","doi-asserted-by":"publisher","first-page":"e0299946","DOI":"10.1371\/journal.pone.0299946","volume":"19","author":"W Cai","year":"2024","unstructured":"Cai W, Qiu T, Hu W, Fang T (2024) Changes in the intestinal microbiota of individuals with non-alcoholic fatty liver disease based on sequencing: an updated systematic review and meta-analysis. PLoS One 19:e0299946. https:\/\/doi.org\/10.1371\/journal.pone.0299946","journal-title":"PLoS One"},{"key":"4_CR13","doi-asserted-by":"publisher","first-page":"112162","DOI":"10.1016\/j.isci.2025.112162","volume":"28","author":"X Cai","year":"2025","unstructured":"Cai X et al (2025) Enriched pathways in gut microbiome predict response to immune checkpoint inhibitor treatment across demographic regions and various cancer types. iScience 28:112162. https:\/\/doi.org\/10.1016\/j.isci.2025.112162","journal-title":"iScience"},{"key":"4_CR14","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","volume":"28","author":"N Chaput","year":"2017","unstructured":"Chaput N et al (2017) Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 28:1368\u20131379. https:\/\/doi.org\/10.1093\/annonc\/mdx108","journal-title":"Ann Oncol"},{"key":"4_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.coi.2018.03.008","volume":"51","author":"S Chaurasiya","year":"2018","unstructured":"Chaurasiya S, Chen NG, Fong Y (2018) Oncolytic viruses and immunity. Curr Opin Immunol 51:83\u201390. https:\/\/doi.org\/10.1016\/j.coi.2018.03.008","journal-title":"Curr Opin Immunol"},{"key":"4_CR16","doi-asserted-by":"publisher","first-page":"1133308","DOI":"10.3389\/fimmu.2023.1133308","volume":"14","author":"C Chen","year":"2023","unstructured":"Chen C, Wang Z, Ding Y, Qin Y (2023) Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Front Immunol 14:1133308. https:\/\/doi.org\/10.3389\/fimmu.2023.1133308","journal-title":"Front Immunol"},{"key":"4_CR17","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/hep.24423","volume":"54","author":"Y Chen","year":"2011","unstructured":"Chen Y et al (2011) Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 54:562\u2013572. https:\/\/doi.org\/10.1002\/hep.24423","journal-title":"Hepatology"},{"key":"4_CR18","doi-asserted-by":"publisher","unstructured":"da Costa VR et al (2021) Exosomes in the tumor microenvironment: from biology to clinical applications. Cells 10 https:\/\/doi.org\/10.3390\/cells10102617","DOI":"10.3390\/cells10102617"},{"key":"4_CR19","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ccr.2012.02.007","volume":"21","author":"DH Dapito","year":"2012","unstructured":"Dapito DH et al (2012) Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21:504\u2013516. https:\/\/doi.org\/10.1016\/j.ccr.2012.02.007","journal-title":"Cancer Cell"},{"key":"4_CR20","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1002\/hep.27376","volume":"61","author":"LD DeLeve","year":"2015","unstructured":"DeLeve LD (2015) Liver sinusoidal endothelial cells in hepatic fibrosis. Hepatology 61:1740\u20131746. https:\/\/doi.org\/10.1002\/hep.27376","journal-title":"Hepatology"},{"key":"4_CR21","doi-asserted-by":"publisher","first-page":"e13768","DOI":"10.1111\/eci.13768","volume":"52","author":"A Di Ciaula","year":"2022","unstructured":"Di Ciaula A, Bonfrate L, Portincasa P (2022) The role of microbiota in nonalcoholic fatty liver disease. Eur J Clin Invest 52:e13768. https:\/\/doi.org\/10.1111\/eci.13768","journal-title":"Eur J Clin Invest"},{"key":"4_CR22","doi-asserted-by":"publisher","unstructured":"Di Palo DM, Garruti G, Di Ciaula A, Molina-Molina E, Shanmugam H, De Angelis M, Portincasa P (2020) Increased colonic permeability and lifestyles as contributing factors to obesity and liver steatosis. Nutrients 12 https:\/\/doi.org\/10.3390\/nu12020564","DOI":"10.3390\/nu12020564"},{"key":"4_CR23","doi-asserted-by":"publisher","first-page":"1254766","DOI":"10.1126\/science.1254766","volume":"349","author":"MS Donia","year":"2015","unstructured":"Donia MS, Fischbach MA (2015) Small molecules from the human microbiota. Science 349:1254766. https:\/\/doi.org\/10.1126\/science.1254766","journal-title":"Science"},{"key":"4_CR24","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991\u2013998. https:\/\/doi.org\/10.1038\/ni1102-991","journal-title":"Nat Immunol"},{"key":"4_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11901-014-0224-8","volume":"13","author":"CC Duwaerts","year":"2014","unstructured":"Duwaerts CC, Maher JJ (2014) Mechanisms of liver injury in non-alcoholic steatohepatitis. Curr Hepatol Rep 13:119\u2013129. https:\/\/doi.org\/10.1007\/s11901-014-0224-8","journal-title":"Curr Hepatol Rep"},{"key":"4_CR26","doi-asserted-by":"publisher","first-page":"2304157","DOI":"10.1080\/19490976.2024.2304157","volume":"16","author":"R Forlano","year":"2024","unstructured":"Forlano R et al (2024) Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus. Gut Microbes 16:2304157. https:\/\/doi.org\/10.1080\/19490976.2024.2304157","journal-title":"Gut Microbes"},{"key":"4_CR27","doi-asserted-by":"publisher","first-page":"1051987","DOI":"10.3389\/fimmu.2022.1051987","volume":"13","author":"F Gao","year":"2022","unstructured":"Gao F et al (2022) The effect of the intratumoral microbiome on tumor occurrence, progression, prognosis and treatment. Front Immunol 13:1051987. https:\/\/doi.org\/10.3389\/fimmu.2022.1051987","journal-title":"Front Immunol"},{"key":"4_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11960","volume":"7","author":"X Gao","year":"2016","unstructured":"Gao X et al (2016) Acetate functions as an epigenetic metabolite to promote lipid synthesis under hypoxia. Nat Commun 7: 11960. https:\/\/doi.org\/10.1038\/ncomms11960","journal-title":"Nat Commun"},{"key":"4_CR29","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/hep.29646","volume":"67","author":"T Garcia-Lezana","year":"2018","unstructured":"Garcia-Lezana T et al (2018) Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis. Hepatology 67:1485\u20131498. https:\/\/doi.org\/10.1002\/hep.29646","journal-title":"Hepatology"},{"key":"4_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1126\/science.aaa4972","volume":"348","author":"WS Garrett","year":"2015","unstructured":"Garrett WS (2015) Cancer and the microbiota. Science 348:80\u201386. https:\/\/doi.org\/10.1126\/science.aaa4972","journal-title":"Science"},{"key":"4_CR31","doi-asserted-by":"publisher","unstructured":"Gebru YA et al (2021) T cell subsets and natural killer cells in the pathogenesis of nonalcoholic fatty liver disease. Int J Mol Sci 22 https:\/\/doi.org\/10.3390\/ijms222212190","DOI":"10.3390\/ijms222212190"},{"key":"4_CR32","doi-asserted-by":"publisher","first-page":"16795","DOI":"10.3748\/wjg.v20.i45.16795","volume":"20","author":"V Giannelli","year":"2014","unstructured":"Giannelli V, Di Gregorio V, Iebba V, Giusto M, Schippa S, Merli M, Thalheimer U (2014) Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis. World J Gastroenterol 20:16795\u201316810. https:\/\/doi.org\/10.3748\/wjg.v20.i45.16795","journal-title":"World J Gastroenterol"},{"key":"4_CR33","doi-asserted-by":"publisher","unstructured":"Giraud J, Saleh M (2021) Host-microbiota interactions in liver inflammation and cancer. Cancers (Basel) 13 https:\/\/doi.org\/10.3390\/cancers13174342","DOI":"10.3390\/cancers13174342"},{"key":"4_CR34","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/jgh.12556","volume":"29","author":"A Goel","year":"2014","unstructured":"Goel A, Gupta M, Aggarwal R (2014) Gut microbiota and liver disease. J Gastroenterol Hepatol 29:1139\u20131148. https:\/\/doi.org\/10.1111\/jgh.12556","journal-title":"J Gastroenterol Hepatol"},{"key":"4_CR35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359:97\u2013103. https:\/\/doi.org\/10.1126\/science.aan4236","journal-title":"Science"},{"key":"4_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.20517\/2394-5079.2022.34","volume":"8","author":"SN Gregory","year":"2022","unstructured":"Gregory SN, Perati SR, Brown ZJ (2022) Alteration in immune function in patients with fatty liver disease. Hepatoma Res 8:31. https:\/\/doi.org\/10.20517\/2394-5079.2022.34","journal-title":"Hepatoma Res"},{"key":"4_CR37","doi-asserted-by":"publisher","first-page":"100818","DOI":"10.1016\/j.neo.2022.100818","volume":"31","author":"ME Griffin","year":"2022","unstructured":"Griffin ME, Hang HC (2022) Microbial mechanisms to improve immune checkpoint blockade responsiveness. Neoplasia 31:100818. https:\/\/doi.org\/10.1016\/j.neo.2022.100818","journal-title":"Neoplasia"},{"key":"4_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cld.2024.08.001","volume":"29","author":"R Gujarathi","year":"2025","unstructured":"Gujarathi R, Klein JA, Liao CY, Pillai A (2025) The changing demographics and epidemiology of hepatocellular carcinoma. Clin Liver Dis 29:1\u201315. https:\/\/doi.org\/10.1016\/j.cld.2024.08.001","journal-title":"Clin Liver Dis"},{"key":"4_CR39","doi-asserted-by":"publisher","unstructured":"Gurbatri CR et al (2020) Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci Transl Med 12 https:\/\/doi.org\/10.1126\/scitranslmed.aax0876","DOI":"10.1126\/scitranslmed.aax0876"},{"key":"4_CR40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/gutjnl-2024-332398","volume":"74","author":"S Ha","year":"2024","unstructured":"Ha S, Wong VW, Zhang X, Yu J (2024) Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma. Gut 74:141\u2013152. https:\/\/doi.org\/10.1136\/gutjnl-2024-332398","journal-title":"Gut"},{"key":"4_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03938-6","volume":"21","author":"Y He","year":"2023","unstructured":"He Y, Zhang Q, Yu X, Zhang S, Guo W (2023) Overview of microbial profiles in human hepatocellular carcinoma and adjacent nontumor tissues. J Transl Med 21: 68. https:\/\/doi.org\/10.1186\/s12967-023-03938-6","journal-title":"J Transl Med"},{"key":"4_CR42","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/nrc1456","volume":"4","author":"CH Heldin","year":"2004","unstructured":"Heldin CH, Rubin K, Pietras K, Ostman A (2004) High interstitial fluid pressure\u2014an obstacle in cancer therapy. Nat Rev Cancer 4:806\u2013813. https:\/\/doi.org\/10.1038\/nrc1456","journal-title":"Nat Rev Cancer"},{"key":"4_CR43","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10809","volume":"482","author":"J Henao-Mejia","year":"2012","unstructured":"Henao-Mejia J et al (2012) Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482:179\u2013185. https:\/\/doi.org\/10.1038\/nature10809","journal-title":"Nature"},{"key":"4_CR44","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1053\/j.gastro.2019.03.013","volume":"157","author":"MB Hilscher","year":"2019","unstructured":"Hilscher MB et al (2019) Mechanical stretch increases expression of CXCL1 in liver sinusoidal endothelial cells to recruit neutrophils, generate sinusoidal microthombi, and promote portal hypertension. Gastroenterology 157:193\u2013209 e199. https:\/\/doi.org\/10.1053\/j.gastro.2019.03.013","journal-title":"Gastroenterology"},{"key":"4_CR45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2019.08.014","volume":"72","author":"J Hou","year":"2020","unstructured":"Hou J, Zhang H, Sun B, Karin M (2020) The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications. J Hepatol 72:167\u2013182. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.014","journal-title":"J Hepatol"},{"key":"4_CR46","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41392-022-00974-4","volume":"7","author":"K Hou","year":"2022","unstructured":"Hou K et al (2022) Microbiota in health and diseases. Signal Transduct Target Ther 7:135. https:\/\/doi.org\/10.1038\/s41392-022-00974-4","journal-title":"Signal Transduct Target Ther"},{"key":"4_CR47","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41591-018-0061-3","volume":"24","author":"L Hoyles","year":"2018","unstructured":"Hoyles L et al (2018) Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med 24:1070\u20131080. https:\/\/doi.org\/10.1038\/s41591-018-0061-3","journal-title":"Nat Med"},{"key":"4_CR48","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hep.32449","volume":"77","author":"C Hu","year":"2023","unstructured":"Hu C et al (2023) Gut microbiota-derived short-chain fatty acids regulate group 3 innate lymphoid cells in HCC. Hepatology 77:48\u201364. https:\/\/doi.org\/10.1002\/hep.32449","journal-title":"Hepatology"},{"key":"4_CR49","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R (2021) Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 18:223\u2013238. https:\/\/doi.org\/10.1038\/s41575-020-00381-6","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4_CR50","doi-asserted-by":"publisher","first-page":"e0098322","DOI":"10.1128\/spectrum.00983-22","volume":"10","author":"JH Huang","year":"2022","unstructured":"Huang JH et al (2022) The intratumoral bacterial metataxonomic signature of hepatocellular carcinoma. Microbiol Spectr 10:e0098322. https:\/\/doi.org\/10.1128\/spectrum.00983-22","journal-title":"Microbiol Spectr"},{"key":"4_CR51","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nature11234","volume":"486","author":"Human Microbiome Project C","year":"2012","unstructured":"Human Microbiome Project C (2012) Structure, function and diversity of the healthy human microbiome. Nature 486:207\u2013214. https:\/\/doi.org\/10.1038\/nature11234","journal-title":"Nature"},{"key":"4_CR52","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jhep.2021.08.012","volume":"75","author":"GN Ioannou","year":"2021","unstructured":"Ioannou GN (2021) Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol 75:1476\u20131484. https:\/\/doi.org\/10.1016\/j.jhep.2021.08.012","journal-title":"J Hepatol"},{"key":"4_CR53","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00281-009-0155-6","volume":"31","author":"H Ishibashi","year":"2009","unstructured":"Ishibashi H, Nakamura M, Komori A, Migita K, Shimoda S (2009) Liver architecture, cell function, and disease. Semin Immunopathol 31:399\u2013409. https:\/\/doi.org\/10.1007\/s00281-009-0155-6","journal-title":"Semin Immunopathol"},{"key":"4_CR54","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/0115680096282503240124104029","volume":"25","author":"P Jain","year":"2025","unstructured":"Jain P, Mohapatra S, Farooq U, Hassan N, Mirza MA, Iqbal Z (2025) An overview of the dichotomous role of microbiota in cancer progression and management. Curr Cancer Drug Targets 25:38\u201348. https:\/\/doi.org\/10.2174\/0115680096282503240124104029","journal-title":"Curr Cancer Drug Targets"},{"key":"4_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-77260-6","volume":"14","author":"HE Jo","year":"2024","unstructured":"Jo HE et al (2024) Stage dependent microbial dynamics in hepatocellular carcinoma and adjacent normal liver tissues. Sci Rep 14: 26092. https:\/\/doi.org\/10.1038\/s41598-024-77260-6","journal-title":"Sci Rep"},{"key":"4_CR56","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","volume":"155","author":"F Kanwal","year":"2018","unstructured":"Kanwal F et al (2018) Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology 155:1828\u20131837 e1822. https:\/\/doi.org\/10.1053\/j.gastro.2018.08.024","journal-title":"Gastroenterology"},{"key":"4_CR57","doi-asserted-by":"publisher","first-page":"686","DOI":"10.21037\/hbsn-24-153","volume":"13","author":"X Ke","year":"2024","unstructured":"Ke X, Wei Q, Sun L, Yang H (2024) Liver microbiome: an intrahepatic resident playing a role in liver diseases. Hepatobiliary Surg Nutr 13:686\u2013689. https:\/\/doi.org\/10.21037\/hbsn-24-153","journal-title":"Hepatobiliary Surg Nutr"},{"key":"4_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89963-1","volume":"11","author":"S Komiyama","year":"2021","unstructured":"Komiyama S, Yamada T, Takemura N, Kokudo N, Hase K, Kawamura YI (2021) Profiling of tumour-associated microbiota in human hepatocellular carcinoma. Sci Rep 11: 10589. https:\/\/doi.org\/10.1038\/s41598-021-89963-1","journal-title":"Sci Rep"},{"key":"4_CR59","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1101\/gr.126573.111","volume":"22","author":"AD Kostic","year":"2012","unstructured":"Kostic AD et al (2012) Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 22:292\u2013298. https:\/\/doi.org\/10.1101\/gr.126573.111","journal-title":"Genome Res"},{"key":"4_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-02072-3","volume":"29","author":"AR Kumar","year":"2024","unstructured":"Kumar AR, Nair B, Kamath AJ, Nath LR, Calina D, Sharifi-Rad J (2024) Impact of gut microbiota on metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma: pathways, diagnostic opportunities and therapeutic advances. Eur J Med Res 29: 485 https:\/\/doi.org\/10.1186\/s40001-024-02072-3","journal-title":"Eur J Med Res"},{"key":"4_CR61","doi-asserted-by":"publisher","unstructured":"Kyriazi AA, Karaglani M, Agelaki S, Baritaki S (2024) Intratumoral microbiome: foe or friend in reshaping the tumor microenvironment landscape? Cells 13. https:\/\/doi.org\/10.3390\/cells13151279","DOI":"10.3390\/cells13151279"},{"key":"4_CR62","doi-asserted-by":"publisher","first-page":"104952","DOI":"10.1016\/j.ebiom.2023.104952","volume":"100","author":"HC Lau","year":"2024","unstructured":"Lau HC et al (2024) Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid. EBioMedicine 100:104952. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104952","journal-title":"EBioMedicine"},{"key":"4_CR63","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nature12506","volume":"500","author":"E Le Chatelier","year":"2013","unstructured":"Le Chatelier E et al (2013) Richness of human gut microbiome correlates with metabolic markers. Nature 500:541\u2013546. https:\/\/doi.org\/10.1038\/nature12506","journal-title":"Nature"},{"key":"4_CR64","doi-asserted-by":"publisher","unstructured":"Leinwand JC et al (2022) Intrahepatic microbes govern liver immunity by programming NKT cells. J Clin Invest 132. https:\/\/doi.org\/10.1172\/JCI151725","DOI":"10.1172\/JCI151725"},{"key":"4_CR65","doi-asserted-by":"publisher","unstructured":"Leong SP, Aktipis A, Maley C (2018) Cancer initiation and progression within the cancer microenvironment. Clin Exp Metastasis. https:\/\/doi.org\/10.1007\/s10585-018-9921-y","DOI":"10.1007\/s10585-018-9921-y"},{"key":"4_CR66","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nrgastro.2016.85","volume":"13","author":"C Leung","year":"2016","unstructured":"Leung C, Rivera L, Furness JB, Angus PW (2016) The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol 13:412\u2013425. https:\/\/doi.org\/10.1038\/nrgastro.2016.85","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4_CR67","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/4441022a","volume":"444","author":"RE Ley","year":"2006","unstructured":"Ley RE, Turnbaugh PJ, Klein S, Gordon JI (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444:1022\u20131023. https:\/\/doi.org\/10.1038\/4441022a","journal-title":"Nature"},{"key":"4_CR68","doi-asserted-by":"publisher","first-page":"E1306","DOI":"10.1073\/pnas.1518189113","volume":"113","author":"J Li","year":"2016","unstructured":"Li J, Sung CY, Lee N, Ni Y, Pihlajamaki J, Panagiotou G, El-Nezami H (2016) Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci USA 113:E1306\u20131315. https:\/\/doi.org\/10.1073\/pnas.1518189113","journal-title":"Proc Natl Acad Sci USA"},{"key":"4_CR69","doi-asserted-by":"publisher","unstructured":"Liu B et al (2022a) Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma. J Immunother Cancer 10 https:\/\/doi.org\/10.1136\/jitc-2021-003069","DOI":"10.1136\/jitc-2021-003069"},{"key":"4_CR70","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1136\/gutjnl-2021-325189","volume":"71","author":"J Liu","year":"2022","unstructured":"Liu J et al. (2022b) Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma. Gut 71:1203\u20131213. https:\/\/doi.org\/10.1136\/gutjnl-2021-325189","journal-title":"Gut"},{"key":"4_CR71","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","volume":"8","author":"D Lin","year":"2023","unstructured":"Lin D, Shen Y, Liang T (2023a) Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther 8:156. https:\/\/doi.org\/10.1038\/s41392-023-01407-6","journal-title":"Signal Transduct Target Ther"},{"key":"4_CR72","doi-asserted-by":"publisher","first-page":"757","DOI":"10.4251\/wjgo.v15.i5.757","volume":"15","author":"Q Lin","year":"2023","unstructured":"Lin Q, Guan SW, Yu HB (2023b) Immuno-oncology-microbiome axis of gastrointestinal malignancy. World J Gastrointest Oncol 15:757\u2013775. https:\/\/doi.org\/10.4251\/wjgo.v15.i5.757","journal-title":"World J Gastrointest Oncol"},{"key":"4_CR73","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-024-02545-9","volume":"41","author":"H Liu","year":"2024","unstructured":"Liu H, Zhang J, Rao Y, Jin S, Zhang C, Bai D (2024) Intratumoral microbiota: an emerging force in diagnosing and treating hepatocellular carcinoma. Med Oncol 41: 300. https:\/\/doi.org\/10.1007\/s12032-024-02545-9","journal-title":"Med Oncol"},{"key":"4_CR74","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.mam.2017.06.002","volume":"56","author":"SL Long","year":"2017","unstructured":"Long SL, Gahan CGM, Joyce SA (2017) Interactions between gut bacteria and bile in health and disease. Mol Aspects Med 56:54\u201365. https:\/\/doi.org\/10.1016\/j.mam.2017.06.002","journal-title":"Mol Aspects Med"},{"key":"4_CR75","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.CD-16-0932","volume":"7","author":"TM Loo","year":"2017","unstructured":"Loo TM et al (2017) Gut microbiota promotes obesity-associated liver cancer through PGE(2)-mediated suppression of antitumor immunity. Cancer Discov 7:522\u2013538. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0932","journal-title":"Cancer Discov"},{"key":"4_CR76","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","volume":"25","author":"R Loomba","year":"2017","unstructured":"Loomba R et al (2017) Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab 25:1054\u20131062 e1055. https:\/\/doi.org\/10.1016\/j.cmet.2017.04.001","journal-title":"Cell Metab"},{"key":"4_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05320-6","volume":"22","author":"W Lu","year":"2024","unstructured":"Lu W, Aihaiti A, Abudukeranmu P, Liu Y, Gao H (2024) Unravelling the role of intratumoral bacteria in digestive system cancers: current insights and future perspectives. J Transl Med 22: 545. https:\/\/doi.org\/10.1186\/s12967-024-05320-6","journal-title":"J Transl Med"},{"key":"4_CR78","doi-asserted-by":"publisher","first-page":"121614","DOI":"10.1016\/j.lfs.2023.121614","volume":"321","author":"L Luo","year":"2023","unstructured":"Luo L, Chang Y, Sheng L (2023) Gut-liver axis in the progression of nonalcoholic fatty liver disease: From the microbial derivatives-centered perspective. Life Sci 321:121614. https:\/\/doi.org\/10.1016\/j.lfs.2023.121614","journal-title":"Life Sci"},{"issue":"Suppl 1","key":"4_CR79","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"McGlynn KA, Petrick JL, El-Serag HB (2021) Epidemiology of hepatocellular carcinoma. Hepatology 73(Suppl 1):4\u201313. https:\/\/doi.org\/10.1002\/hep.31288","journal-title":"Hepatology"},{"key":"4_CR80","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1002\/hep.22848","volume":"49","author":"L Miele","year":"2009","unstructured":"Miele L et al (2009) Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49:1877\u20131887. https:\/\/doi.org\/10.1002\/hep.22848","journal-title":"Hepatology"},{"key":"4_CR81","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/mi.2014.4","volume":"7","author":"MJ Miller","year":"2014","unstructured":"Miller MJ, Knoop KA, Newberry RD (2014) Mind the GAPs: insights into intestinal epithelial barrier maintenance and luminal antigen delivery. Mucosal Immunol 7:452\u2013454. https:\/\/doi.org\/10.1038\/mi.2014.4","journal-title":"Mucosal Immunol"},{"key":"4_CR82","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.jhep.2022.08.028","volume":"77","author":"EK Mitten","year":"2022","unstructured":"Mitten EK, Baffy G (2022) Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease. J Hepatol 77:1642\u20131656. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.028","journal-title":"J Hepatol"},{"key":"4_CR83","doi-asserted-by":"publisher","first-page":"2","DOI":"10.20517\/mtod.2022.37","volume":"3","author":"EK Mitten","year":"2023","unstructured":"Mitten EK, Baffy G (2023) Mechanobiology in the development and progression of non-alcoholic fatty liver disease: an updated review. Metabolism and Target Organ Damage 3:2. https:\/\/doi.org\/10.20517\/mtod.2022.37","journal-title":"Metabolism and Target Organ Damage"},{"key":"4_CR84","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.neo.2018.05.002","volume":"20","author":"F Morgillo","year":"2018","unstructured":"Morgillo F et al (2018) Carcinogenesis as a result of multiple inflammatory and oxidative hits: a comprehensive review from tumor microenvironment to gut microbiota. Neoplasia 20:721\u2013733. https:\/\/doi.org\/10.1016\/j.neo.2018.05.002","journal-title":"Neoplasia"},{"key":"4_CR85","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.tem.2013.05.009","volume":"24","author":"AR Moschen","year":"2013","unstructured":"Moschen AR, Kaser S, Tilg H (2013) Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol Metab 24:537\u2013545. https:\/\/doi.org\/10.1016\/j.tem.2013.05.009","journal-title":"Trends Endocrinol Metab"},{"key":"4_CR86","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","volume":"71","author":"J Mouries","year":"2019","unstructured":"Mouries J et al (2019) Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol 71:1216\u20131228. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.005","journal-title":"J Hepatol"},{"key":"4_CR87","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1126\/science.aay9189","volume":"368","author":"D Nejman","year":"2020","unstructured":"Nejman D et al (2020) The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 368:973\u2013980. https:\/\/doi.org\/10.1126\/science.aay9189","journal-title":"Science"},{"key":"4_CR88","doi-asserted-by":"publisher","first-page":"954869","DOI":"10.3389\/fimmu.2022.954869","volume":"13","author":"N Ortiz-Lopez","year":"2022","unstructured":"Ortiz-Lopez N et al (2022) The immune response as a therapeutic target in non-alcoholic fatty liver disease. Front Immunol 13:954869. https:\/\/doi.org\/10.3389\/fimmu.2022.954869","journal-title":"Front Immunol"},{"key":"4_CR89","doi-asserted-by":"publisher","unstructured":"Pallozzi M et al (2024) Role of gut microbial metabolites in the pathogenesis of primary liver cancers. Nutrients 16 https:\/\/doi.org\/10.3390\/nu16142372","DOI":"10.3390\/nu16142372"},{"key":"4_CR90","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/jgh.15713","volume":"37","author":"Y Pan","year":"2022","unstructured":"Pan Y, Zhang X (2022) Diet and gut microbiome in fatty liver and its associated liver cancer. J Gastroenterol Hepatol 37:7\u201314. https:\/\/doi.org\/10.1111\/jgh.15713","journal-title":"J Gastroenterol Hepatol"},{"key":"4_CR91","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.14309\/ajg.0000000000000715","volume":"115","author":"ND Parikh","year":"2020","unstructured":"Parikh ND, Singal AG, Hutton DW, Tapper EB (2020) Cost-effectiveness of hepatocellular carcinoma surveillance: an assessment of benefits and harms. Am J Gastroenterol 115:1642\u20131649. https:\/\/doi.org\/10.14309\/ajg.0000000000000715","journal-title":"Am J Gastroenterol"},{"key":"4_CR92","doi-asserted-by":"publisher","unstructured":"Park JW et al (2021) Role of microbiota-derived metabolites in alcoholic and non-alcoholic fatty liver diseases. Int J Mol Sci 23 https:\/\/doi.org\/10.3390\/ijms23010426","DOI":"10.3390\/ijms23010426"},{"key":"4_CR93","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1423-0127-17-21","volume":"17","author":"S Patyar","year":"2010","unstructured":"Patyar S, Joshi R, Byrav DS, Prakash A, Medhi B, Das BK (2010) Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci 17:21. https:\/\/doi.org\/10.1186\/1423-0127-17-21","journal-title":"J Biomed Sci"},{"key":"4_CR94","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ijc.32723","volume":"147","author":"JL Petrick","year":"2020","unstructured":"Petrick JL et al (2020) International trends in hepatocellular carcinoma incidence, 1978-2012. Int J Cancer 147:317\u2013330. https:\/\/doi.org\/10.1002\/ijc.32723","journal-title":"Int J Cancer"},{"key":"4_CR95","doi-asserted-by":"publisher","unstructured":"Piscaglia F et al (2015) Clinical patterns of hepatocellular carcinoma (HCC) in non alcoholic fatty liver disease (NAFLD): a multicenter prospective study. Hepatology https:\/\/doi.org\/10.1002\/hep.28368","DOI":"10.1002\/hep.28368"},{"key":"4_CR96","doi-asserted-by":"publisher","unstructured":"Poeta M, Pierri L, Vajro P (2017) Gut-liver axis derangement in non-alcoholic fatty liver disease. Children (Basel) 4 https:\/\/doi.org\/10.3390\/children4080066","DOI":"10.3390\/children4080066"},{"key":"4_CR97","doi-asserted-by":"publisher","first-page":"e0321189","DOI":"10.1371\/journal.pone.0321189","volume":"20","author":"K Pomej","year":"2025","unstructured":"Pomej K et al (2025) Study protocol: fecal microbiota transplant combined with Atezolizumab\/Bevacizumab in patients with hepatocellular carcinoma who failed to achieve or maintain objective response to Atezolizumab\/Bevacizumab\u2014the FAB-HCC pilot study. PLoS One 20:e0321189. https:\/\/doi.org\/10.1371\/journal.pone.0321189","journal-title":"PLoS One"},{"key":"4_CR98","doi-asserted-by":"publisher","unstructured":"Portincasa P et al (2021) Intestinal barrier and permeability in health, obesity and NAFLD. Biomedicines 10 https:\/\/doi.org\/10.3390\/biomedicines10010083","DOI":"10.3390\/biomedicines10010083"},{"key":"4_CR99","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejim.2023.10.002","volume":"119","author":"P Portincasa","year":"2024","unstructured":"Portincasa P et al (2024) Gut microbes in metabolic disturbances. Promising role for therapeutic manipulations?. Eur J Intern Med 119:13\u201330. https:\/\/doi.org\/10.1016\/j.ejim.2023.10.002","journal-title":"Eur J Intern Med"},{"key":"4_CR100","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nature08821","volume":"464","author":"J Qin","year":"2010","unstructured":"Qin J et al (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464:59\u201365. https:\/\/doi.org\/10.1038\/nature08821","journal-title":"Nature"},{"key":"4_CR101","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/hep4.1908","volume":"6","author":"D Qu","year":"2022","unstructured":"Qu D, Wang Y, Xia Q, Chang J, Jiang X, Zhang H (2022) Intratumoral microbiome of human primary liver cancer. Hepatol Commun 6:1741\u20131752. https:\/\/doi.org\/10.1002\/hep4.1908","journal-title":"Hepatol Commun"},{"key":"4_CR102","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.jhep.2012.11.023","volume":"58","author":"EM Quigley","year":"2013","unstructured":"Quigley EM, Stanton C, Murphy EF (2013) The gut microbiota and the liver. Pathophysiological and clinical implications. J Hepatol 58:1020\u20131027. https:\/\/doi.org\/10.1016\/j.jhep.2012.11.023","journal-title":"J Hepatol"},{"key":"4_CR103","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/978-1-4939-9424-3_31","volume":"1982","author":"B Rada","year":"2019","unstructured":"Rada B (2019) Neutrophilextracellular traps. Methods Mol Biol 1982:517\u2013528. https:\/\/doi.org\/10.1007\/978-1-4939-9424-3_31","journal-title":"Methods Mol Biol"},{"key":"4_CR104","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1080\/1040841X.2022.2142091","volume":"49","author":"T Ralli","year":"2023","unstructured":"Ralli T, Saifi Z, Tyagi N, Vidyadhari A, Aeri V, Kohli K (2023) Deciphering the role of gut metabolites in non-alcoholic fatty liver disease. Crit Rev Microbiol 49:815\u2013833. https:\/\/doi.org\/10.1080\/1040841X.2022.2142091","journal-title":"Crit Rev Microbiol"},{"key":"4_CR105","doi-asserted-by":"publisher","first-page":"1526967","DOI":"10.3389\/fimmu.2025.1526967","volume":"16","author":"S Ren","year":"2025","unstructured":"Ren S et al (2025) Emerging insights into the gut microbiota as a key regulator of immunity and response to immunotherapy in hepatocellular carcinoma. Front Immunol 16:1526967. https:\/\/doi.org\/10.3389\/fimmu.2025.1526967","journal-title":"Front Immunol"},{"key":"4_CR106","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1002\/hep4.1923","volume":"6","author":"RF Reveron-Thornton","year":"2022","unstructured":"Reveron-Thornton RF et al (2022) Global and regional long-term survival following resection for HCC in the recent decade: a meta-analysis of 110 studies. Hepatol Commun 6:1813\u20131826. https:\/\/doi.org\/10.1002\/hep4.1923","journal-title":"Hepatol Commun"},{"key":"4_CR107","doi-asserted-by":"publisher","first-page":"382","DOI":"10.4161\/gmic.25723","volume":"4","author":"JM Ridlon","year":"2013","unstructured":"Ridlon JM, Alves JM, Hylemon PB, Bajaj JS (2013) Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. Gut Microbes 4:382\u2013387. https:\/\/doi.org\/10.4161\/gmic.25723","journal-title":"Gut Microbes"},{"key":"4_CR108","doi-asserted-by":"publisher","first-page":"704942","DOI":"10.3389\/fimmu.2021.704942","volume":"12","author":"M Roberto","year":"2021","unstructured":"Roberto M, Carconi C, Cerreti M, Schipilliti FM, Botticelli A, Mazzuca F, Marchetti P (2021) The challenge of ICIs resistance in solid tumours: could microbiota and its diversity be our secret weapon?. Front Immunol 12:704942. https:\/\/doi.org\/10.3389\/fimmu.2021.704942","journal-title":"Front Immunol"},{"key":"4_CR109","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B et al (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359:91\u201397. https:\/\/doi.org\/10.1126\/science.aan3706","journal-title":"Science"},{"key":"4_CR110","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H et al (2022) Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol 77:1598\u20131606. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.021","journal-title":"J Hepatol"},{"key":"4_CR111","doi-asserted-by":"publisher","unstructured":"Scarpellini E, Scarlata GGM, Santori V, Scarcella M, Kobyliak N, Abenavoli L (2024) Gut microbiota, deranged immunity, and hepatocellular carcinoma. Biomedicines 12. https:\/\/doi.org\/10.3390\/biomedicines12081797","DOI":"10.3390\/biomedicines12081797"},{"key":"4_CR112","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1053\/j.gastro.2012.11.005","volume":"144","author":"A Schirbel","year":"2013","unstructured":"Schirbel A et al (2013) Pro-angiogenic activity of TLRs and NLRs: a novel link between gut microbiota and intestinal angiogenesis. Gastroenterology 144:613\u2013623 e619. https:\/\/doi.org\/10.1053\/j.gastro.2012.11.005","journal-title":"Gastroenterology"},{"key":"4_CR113","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1053\/j.gastro.2014.01.020","volume":"146","author":"B Schnabl","year":"2014","unstructured":"Schnabl B, Brenner DA (2014) Interactions between the intestinal microbiome and liver diseases. Gastroenterology 146:1513\u20131524. https:\/\/doi.org\/10.1053\/j.gastro.2014.01.020","journal-title":"Gastroenterology"},{"key":"4_CR114","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.chom.2017.11.004","volume":"23","author":"BO Schroeder","year":"2018","unstructured":"Schroeder BO, Birchenough GMH, Stahlman M, Arike L, Johansson MEV, Hansson GC, Backhed F (2018) Bifidobacteria or fiber protects against diet-induced microbiota-mediated colonic mucus deterioration. Cell Host Microbe 23:27\u201340 e27. https:\/\/doi.org\/10.1016\/j.chom.2017.11.004","journal-title":"Cell Host Microbe"},{"key":"4_CR115","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jhep.2019.08.016","volume":"72","author":"RF Schwabe","year":"2020","unstructured":"Schwabe RF, Greten TF (2020) Gut microbiome in HCC\u2014mechanisms, diagnosis and therapy. J Hepatol 72:230\u2013238. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.016","journal-title":"J Hepatol"},{"key":"4_CR116","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/nrc3610","volume":"13","author":"RF Schwabe","year":"2013","unstructured":"Schwabe RF, Jobin C (2013) The microbiome and cancer. Nat Rev Cancer 13:800\u2013812. https:\/\/doi.org\/10.1038\/nrc3610","journal-title":"Nat Rev Cancer"},{"key":"4_CR117","doi-asserted-by":"publisher","first-page":"e1002533","DOI":"10.1371\/journal.pbio.1002533","volume":"14","author":"R Sender","year":"2016","unstructured":"Sender R, Fuchs S, Milo R (2016) Revised estimates for the number of human and bacteria cells in the body. PLoS Biol 14:e1002533. https:\/\/doi.org\/10.1371\/journal.pbio.1002533","journal-title":"PLoS Biol"},{"key":"4_CR118","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-0030-1247128","volume":"30","author":"M Sherman","year":"2010","unstructured":"Sherman M (2010) Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 30:3\u201316. https:\/\/doi.org\/10.1055\/s-0030-1247128","journal-title":"Semin Liver Dis"},{"key":"4_CR119","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1126\/science.1241165","volume":"341","author":"PM Smith","year":"2013","unstructured":"Smith PM et al (2013) The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341:569\u2013573. https:\/\/doi.org\/10.1126\/science.1241165","journal-title":"Science"},{"key":"4_CR120","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","volume":"79","author":"Q Song","year":"2023","unstructured":"Song Q et al (2023) Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma. J Hepatol 79:1352\u20131365. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.005","journal-title":"J Hepatol"},{"key":"4_CR121","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1136\/gutjnl-2019-318811","volume":"69","author":"S Sookoian","year":"2020","unstructured":"Sookoian S, Salatino A, Castano GO, Landa MS, Fijalkowky C, Garaycoechea M, Pirola CJ (2020) Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease. Gut 69:1483\u20131491. https:\/\/doi.org\/10.1136\/gutjnl-2019-318811","journal-title":"Gut"},{"key":"4_CR122","doi-asserted-by":"publisher","unstructured":"Sun L, Dai JJ, Hu WF, Wang J (2016) Expression of toll-like receptors in hepatic cirrhosis and hepatocellular carcinoma. Genet Mol Res 15 https:\/\/doi.org\/10.4238\/gmr.15027419","DOI":"10.4238\/gmr.15027419"},{"key":"4_CR123","doi-asserted-by":"publisher","first-page":"881","DOI":"10.4103\/jcrt.jcrt_139_22","volume":"19","author":"P Sun","year":"2023","unstructured":"Sun P, Li Z, Zhang B (2023) Characterization of disease-associated microbiota in hepatocellular carcinoma. J Cancer Res Ther 19:881\u2013891. https:\/\/doi.org\/10.4103\/jcrt.jcrt_139_22","journal-title":"J Cancer Res Ther"},{"key":"4_CR124","doi-asserted-by":"publisher","first-page":"C1200","DOI":"10.1152\/ajpcell.00062.2020","volume":"318","author":"X Sun","year":"2020","unstructured":"Sun X, Harris EN (2020) New aspects of hepatic endothelial cells in physiology and nonalcoholic fatty liver disease. Am J Physiol Cell Physiol 318:C1200\u2013C1213. https:\/\/doi.org\/10.1152\/ajpcell.00062.2020","journal-title":"Am J Physiol Cell Physiol"},{"key":"4_CR125","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrgastro.2015.94","volume":"12","author":"G Szabo","year":"2015","unstructured":"Szabo G, Petrasek J (2015) Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol 12:387\u2013400. https:\/\/doi.org\/10.1038\/nrgastro.2015.94","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4_CR126","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","volume":"34","author":"H Tilg","year":"2022","unstructured":"Tilg H, Adolph TE, Trauner M (2022) Gut-liver axis: pathophysiological concepts and clinical implications. Cell Metab 34:1700\u20131718. https:\/\/doi.org\/10.1016\/j.cmet.2022.09.017","journal-title":"Cell Metab"},{"key":"4_CR127","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1136\/gutjnl-2016-312729","volume":"65","author":"H Tilg","year":"2016","unstructured":"Tilg H, Cani PD, Mayer EA (2016) Gut microbiome and liver diseases. Gut 65:2035\u20132044. https:\/\/doi.org\/10.1136\/gutjnl-2016-312729","journal-title":"Gut"},{"key":"4_CR128","doi-asserted-by":"publisher","unstructured":"Todorovic N, Martinelli S, Nannini G, Weiskirchen R, Amedei A (2024) Etiology-dependent microbiome differences in hepatocellular carcinoma development. Int J Mol Sci 25 https:\/\/doi.org\/10.3390\/ijms252413510","DOI":"10.3390\/ijms252413510"},{"key":"4_CR129","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3748\/wjg.v29.i2.343","volume":"29","author":"CV Tovo","year":"2023","unstructured":"Tovo CV et al (2023) Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis. World J Gastroenterol 29:343\u2013356. https:\/\/doi.org\/10.3748\/wjg.v29.i2.343","journal-title":"World J Gastroenterol"},{"key":"4_CR130","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M Vetizou","year":"2015","unstructured":"Vetizou M et al (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350:1079\u20131084. https:\/\/doi.org\/10.1126\/science.aad1329","journal-title":"Science"},{"key":"4_CR131","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/gutjnl-2021-324915","volume":"72","author":"A Vitale","year":"2023","unstructured":"Vitale A et al (2023) Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut 72:141\u2013152. https:\/\/doi.org\/10.1136\/gutjnl-2021-324915","journal-title":"Gut"},{"key":"4_CR132","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1152\/physrev.00027.2008","volume":"89","author":"B Vollmar","year":"2009","unstructured":"Vollmar B, Menger MD (2009) The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair. Physiol Rev 89:1269\u20131339. https:\/\/doi.org\/10.1152\/physrev.00027.2008","journal-title":"Physiol Rev"},{"key":"4_CR133","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41423-020-00592-6","volume":"18","author":"R Wang","year":"2021","unstructured":"Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H (2021) Gut microbiome, liver immunology, and liver diseases. Cell Mol Immunol 18:4\u201317. https:\/\/doi.org\/10.1038\/s41423-020-00592-6","journal-title":"Cell Mol Immunol"},{"key":"4_CR134","doi-asserted-by":"publisher","unstructured":"Wang X, Zhang L, Dong B (2024) Molecular mechanisms in MASLD\/MASH-related HCC. Hepatology. https:\/\/doi.org\/10.1097\/HEP.0000000000000786","DOI":"10.1097\/HEP.0000000000000786"},{"key":"4_CR135","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41420-025-02413-z","volume":"11","author":"Y Wang","year":"2025","unstructured":"Wang Y et al (2025) Roles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota. Cell Death Discov 11:140. https:\/\/doi.org\/10.1038\/s41420-025-02413-z","journal-title":"Cell Death Discov"},{"key":"4_CR136","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jhep.2017.05.007","volume":"67","author":"R Wiest","year":"2017","unstructured":"Wiest R, Albillos A, Trauner M, Bajaj JS, Jalan R (2017) Targeting the gut-liver axis in liver disease. J Hepatol 67:1084\u20131103. https:\/\/doi.org\/10.1016\/j.jhep.2017.05.007","journal-title":"J Hepatol"},{"key":"4_CR137","doi-asserted-by":"publisher","first-page":"e2200470","DOI":"10.1002\/advs.202200470","volume":"9","author":"Y Xie","year":"2022","unstructured":"Xie Y et al (2022) Microbiota in tumors: from understanding to application. Adv Sci (Weinh) 9:e2200470. https:\/\/doi.org\/10.1002\/advs.202200470","journal-title":"Adv Sci (Weinh)"},{"key":"4_CR138","doi-asserted-by":"publisher","unstructured":"Xirouchakis E, Pelekanos A, Xirouchakis S, Kranidioti H, Manolakopoulos S (2025) A systematic review of microbiota in cirrhosis: a change towards a more pathogenic predisposition. Int J Mol Sci 26 https:\/\/doi.org\/10.3390\/ijms26020527","DOI":"10.3390\/ijms26020527"},{"key":"4_CR139","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41392-022-01159-9","volume":"7","author":"C Xue","year":"2022","unstructured":"Xue C et al (2022) Intratumoral bacteria interact with metabolites and genetic alterations in hepatocellular carcinoma. Signal Transduct Target Ther 7:335. https:\/\/doi.org\/10.1038\/s41392-022-01159-9","journal-title":"Signal Transduct Target Ther"},{"key":"4_CR140","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-022-01304-4","volume":"8","author":"L Yang","year":"2023","unstructured":"Yang L, Li A, Wang Y, Zhang Y (2023a) Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy. Signal Transduct Target Ther 8:35. https:\/\/doi.org\/10.1038\/s41392-022-01304-4","journal-title":"Signal Transduct Target Ther"},{"key":"4_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35861-1","volume":"14","author":"M Yang","year":"2023","unstructured":"Yang M et al (2023b) Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol. Nat Commun 14: 228. https:\/\/doi.org\/10.1038\/s41467-023-35861-1","journal-title":"Nat Commun"},{"key":"4_CR142","doi-asserted-by":"publisher","unstructured":"Younossi ZM, Kalligeros M, Henry L (2024) Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol https:\/\/doi.org\/10.3350\/cmh.2024.0431","DOI":"10.3350\/cmh.2024.0431"},{"key":"4_CR143","doi-asserted-by":"publisher","unstructured":"Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, Hunt S (2015) Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology https:\/\/doi.org\/10.1002\/hep.28123","DOI":"10.1002\/hep.28123"},{"key":"4_CR144","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1111\/bph.15046","volume":"177","author":"C Zhang","year":"2020","unstructured":"Zhang C et al (2020) Direct inhibition of the TLR4\/MyD88 pathway by geniposide suppresses HIF-1alpha-independent VEGF expression and angiogenesis in hepatocellular carcinoma. Br J Pharmacol 177:3240\u20133257. https:\/\/doi.org\/10.1111\/bph.15046","journal-title":"Br J Pharmacol"},{"key":"4_CR145","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jhep.2020.09.032","volume":"74","author":"C Zhu","year":"2021","unstructured":"Zhu C et al (2021) Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features. J Hepatol 74:613\u2013626. https:\/\/doi.org\/10.1016\/j.jhep.2020.09.032","journal-title":"J Hepatol"},{"key":"4_CR146","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/hep.26093","volume":"57","author":"L Zhu","year":"2013","unstructured":"Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR (2013) Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 57:601\u2013609. https:\/\/doi.org\/10.1002\/hep.26093","journal-title":"Hepatology"}],"container-title":["Advances in Experimental Medicine and Biology","Cancer Metabolic Remodeling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-032-12166-0_4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:15:08Z","timestamp":1783768508000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-032-12166-0_4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9783032121653","9783032121660"],"references-count":146,"URL":"https:\/\/doi.org\/10.1007\/978-3-032-12166-0_4","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"12 July 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}